Cancer Research4d
Loss–Translocation–Amplification Chromothripsis Drives Osteosarcoma Evolution
Main Finding: High-grade osteosarcomas frequently exhibit a loss–translocation–amplification (LTA) pattern of chromothripsis that inactivates TP53 and amplifies oncogenes. Concept: Ongoing ...
Cancer Research5d
15 Novel Cancer Drugs OK’d by FDA in 2024
The FDA’s Center for Drug Evaluation and Research issued its annual report on the approval of drugs, which announced that the agency OK’d 50 novel drugs in 2024, 15 of which were related to cancer ...
Cancer Research4d
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. *Corresponding Author: Jann N. Sarkaria, Department of Radiation Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905.
Cancer Research5d
Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...
Cancer Research5d
NSF Payment System Back Online
The U.S. National Science Foundation (NSF) announced that payments have been restored to the researchers who receive funding from the independent federal agency. Grant-recipients’ salaries were ...
Cancer Research4d
Selected Articles from This Issue
Trophoblast cell surface antigen 2 (TROP2) is a promising target for cancer therapy. Here, Li and colleagues present the preclinical evaluation of OBI-992, a TROP2-targeted antibody-drug conjugate ...
Cancer Research4d
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation
1Department of Radiation Oncology, Inselspital Bern University Hospital, Bern, Switzerland. 2Department for BioMedical Research, Radiation Oncology, University of Bern, Bern, Switzerland. 3Graduate ...
Cancer Research5d
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
1Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2Department of Surgery, Keio ...
Cancer Research5d
RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different
1Division of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany. 2German Cancer Consortium (DKTK), A Partnership Between LMU Hospital and DKFZ Heidelberg, Munich, Germany.
Cancer Research5d
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
1Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Quebec, Canada. *Corresponding Author: Sébastien Perreault, Department of Neurosciences, University of Montreal, CHU ...
Cancer Research5d
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...
Cancer Research5d
Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models
1Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.